Anti-inflammatory precision from three amino acids
Topical, Oral, Injection, Nasal · 503A Compounding
Educational content. This page describes KPV for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Researched and maintained by the PepHookup team. Regulatory status last verified April 12, 2026.
Enters cells through the PepT1 transporter, accumulates in the nucleus, and competitively blocks the p65/RelA subunit from binding importin-alpha3. This stops NF-kB from reaching DNA and switching on pro-inflammatory genes, lowering TNF-alpha, IL-6, IL-8, and MMP-9 in cell models.[3]
Oral KPV lowered the severity of both DSS and TNBS colitis in mice, and rescued all treated animals from death during DSS colitis even when they lacked functional MC1R receptors. This points to an anti-inflammatory mechanism independent of melanocortin receptor signaling.[1][2]
Topical alpha-MSH(11-13) produced complete corneal re-epithelialization in 100 percent of treated rabbit eyes at 60 hours versus zero placebo controls, through a nitric oxide-dependent mechanism.[7]
KPV (Lys-Pro-Val) is a tripeptide corresponding to the three C-terminal residues, positions 11 through 13, of alpha-melanocyte-stimulating hormone (alpha-MSH). Decades of melanocortin research established that this fragment retains much of alpha-MSH's anti-inflammatory activity while lacking the N-terminal sequence required for pigmentation. It is a small molecule, with a molecular formula of C16H30N4O4 and a molecular weight of roughly 342 daltons.
What sets KPV apart from the parent hormone is how cleanly it separates anti-inflammatory action from melanocortin signaling. In intestinal and immune cells it enters through the PepT1 oligopeptide transporter, reaches the nucleus, and directly interferes with NF-kB rather than working primarily through receptor-driven cAMP. That distinction is why it has been studied as an anti-inflammatory tool without the pigmentation effects of full alpha-MSH.
The honest framing on evidence is important. KPV is not FDA-approved for any indication, and no published human clinical trials of KPV exist. The data summarized here come from cell-culture experiments, animal models of colitis and dermatitis, and one human-skin permeation study. The most authoritative synthesis remains a 2008 Endocrine Reviews review of alpha-MSH and its tripeptides.
KPV enters cells via PepT1 (SLC15A1), an oligopeptide transporter expressed in intestinal epithelium and upregulated at sites of intestinal inflammation. Once inside a colonocyte or immune cell, nanomolar KPV suppresses NF-kB and MAP kinase signaling and reduces pro-inflammatory cytokine secretion. In mice, the anti-inflammatory benefit of oral KPV is lost when PepT1 is absent, which establishes the transporter as essential to its action in the gut.
At the molecular level, KPV accumulates in the nucleus and competitively inhibits the interaction between the NF-kB p65/RelA subunit and importin-alpha3, specifically the importin armadillo arm domains 7 and 8. This blocks the nuclear import step NF-kB requires to reach DNA. KPV does not stop the upstream events: IkBa phosphorylation and degradation proceed normally, so the peptide intercepts the pathway at the nuclear-entry checkpoint rather than shutting it off at the source. Downstream, this lowers TNF-alpha, IL-1beta, IL-6, IL-8, and MMP-9 in cell models.
Because PepT1 expression rises in inflamed tissue, KPV behaves as if it self-targets the gut, concentrating where it is most needed. This property has driven interest in oral formulations and nanoparticle delivery systems for inflammatory bowel conditions. A separate body of work in skin and eye models suggests KPV also calms keratinocyte inflammation and supports epithelial wound repair, though that evidence is preclinical.
Anti-inflammatory precision from three amino acids
KPV enters cells through the PepT1 oligopeptide transporter and blocks NF-kB nuclear import by competitively inhibiting p65/RelA binding to importin-alpha3. Because it intercepts the pathway at the nuclear-entry step rather than upstream, it lowers TNF-alpha, IL-1beta, IL-6, IL-8, and MMP-9 without broadly shutting down the immune response. The effect is independent of melanocortin receptor signaling and does not depend on cAMP elevation.
KPV was transported into cells via PepT1. At nanomolar concentrations it suppressed NF-kB and MAP kinase signaling and reduced pro-inflammatory cytokine secretion. Orally administered KPV decreased the incidence and severity of both DSS and TNBS colitis. This is a preclinical study, not a human trial.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D · Gastroenterology, 134(1):166-178 (2008) · PubMed
KPV produced earlier recovery, stronger weight regain, reduced inflammatory infiltrates, and lower colonic myeloperoxidase. It rescued all treated animals from death during DSS colitis even in MC1R-deficient mice, indicating the effect does not require melanocortin-1 receptor signaling.
Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, et al. · Inflammatory Bowel Diseases, 14(3):324-331 (2008) · PubMed
KPV entered cells, accumulated in the nucleus, and competitively inhibited p65/RelA binding to the importin-alpha3 site, implicating importin armadillo domains 7 and 8. It did not block upstream IkBa phosphorylation. KPV reduced IL-8 and eotaxin secretion and MMP-9 activity.
Land SC · International Journal of Physiology, Pathophysiology and Pharmacology, 4(2):59-73 (2012) · PubMed
PepT1 overexpression increased tumor burden and inflammation, while KPV prevented carcinogenesis in wild-type mice but had no effect in PepT1-deficient animals, confirming PepT1-dependent action. Human colorectal tumors showed elevated PepT1 versus normal tissue.
Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M, et al. · Cellular and Molecular Gastroenterology and Hepatology, 2(3):340-357 (2016) · PubMed
Hyaluronic acid-functionalized KPV nanoparticles (around 272 nm) embedded in a chitosan/alginate hydrogel targeted colonic epithelium and macrophages, accelerated mucosal healing, and downregulated TNF-alpha more effectively than uncoated particles, with no observed cytotoxicity.
Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, et al. · Molecular Therapy, 25(7):1628-1640 (2017) · PubMed
Passive KPV permeation was below detection. Microneedle treatment raised it to 4.4 mcg/cm2/h, and adding anodal iontophoresis increased the rate roughly 35-fold over microneedles alone, showing that physical enhancement is needed for meaningful topical delivery.
Pawar K, Kolli CS, Rangari VK, Babu RJ · Journal of Pharmaceutical Sciences, 106(7):1814-1820 (2017) · PubMed
start low, go slow
Subcutaneous Injection
Oral
Topical
Subcutaneous Injection: A commonly cited research-context range. No human clinical trial has validated any KPV dose, so a licensed provider determines whether and how it is used.
Oral: Free oral KPV is degraded in the GI tract and poorly absorbed. Nanoparticle and hydrogel delivery markedly improved efficacy in animal colitis models, so formulation matters for oral use.
Topical: The rabbit corneal study used 30 mcL drops at 1 to 10 mg/mL four times daily. Human-skin work shows simple topical KPV barely penetrates without microneedles or iontophoresis.
Dosing is determined by a licensed provider based on the specific condition, body weight, and goals. The figures here are educational reference points drawn from preclinical work and allometric scaling, not validated human protocols.
No formal Phase I human safety trial of KPV has been published. Every efficacy and safety figure summarized on this page comes from cell culture, animal models, or ex vivo human tissue.
Oral bioavailability of free KPV is limited by GI degradation. Nanoparticle and hydrogel delivery systems substantially outperformed free peptide in animal models, which suggests the delivery system can matter as much as the dose.
The small size of KPV and its origin as a natural alpha-MSH fragment suggest a low immunogenicity profile, but the FDA has cited immunogenicity and peptide-related impurity concerns for compounded KPV, and human safety has not been established.
In the published preclinical record, KPV showed no cytotoxicity across macrophages, colonic epithelial cells, and bronchial epithelial cells, including after prolonged exposure in the nanoparticle study. Related alpha-MSH tripeptide work has not flagged acute toxicity at the doses tested.
Unlike broad immunosuppressants, KPV modulates inflammation specifically at the NF-kB nuclear-import step rather than globally suppressing immunity, and notably enhanced rather than impaired neutrophil killing of pathogens in antimicrobial studies. No increased infection susceptibility has been reported in preclinical work.
The central safety limitation is the absence of any human clinical trial. The FDA has cited immunogenicity and peptide-related impurity concerns for KPV as a compounded substance. The endogenous origin of KPV is reassuring in principle but does not substitute for human data.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| KPV | Anti-Inflammatory & Wound Healing | Injection, Oral, Topical, Nasal | 4 to 8 weeks | One of the smallest anti-inflammatory peptides, blocking NF-kB nuclear import via PepT1-mediated uptake without melanocortin receptor binding, cAMP elevation, or pigmentation |
| GHK-Cu | Anti-Aging & Skin Regeneration | Topical, Injection | 8-12 weeks | A naturally occurring copper-carrier peptide that rebuilds the skin matrix and, per gene-expression analysis, shifts expression of about a third of human genes toward repair |
| Glutathione | Antioxidant & Detoxification | IV, Oral, Sublingual, Topical | Ongoing supplementation | The body's own master antioxidant, with controlled human data showing oral and sublingual forms can raise body stores and immune markers |
| BPC-157 | Recovery & Healing | Injection, Oral | 4–8 weeks | Unusually stable in gastric acid; broad multi-system healing signal, though evidence is largely preclinical |
| Thymosin Alpha-1 | Immune Support | Injection | 6-12 months (chronic) / short courses (acute) | Bidirectional immunomodulation that can strengthen suppressed immunity while helping temper hyperinflammation; approved as a pharmaceutical in 35+ countries |
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.
Listed in Category 2. FDA cited immunogenicity and peptide-related impurity concerns, as well as a lack of human safety data. Not eligible for compounding under the interim policy.
Listed as 'KPV' in 503A Category 2
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Land SC “Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.” International Journal of Physiology, Pathophysiology and Pharmacology, 4(2):59-73 (2012)
Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M, et al. “Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.” Cellular and Molecular Gastroenterology and Hepatology, 2(3):340-357 (2016)
Brzoska T, Luger TA, Maaser C, Abels C, Bohm M “alpha-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.” Endocrine Reviews, 29(5):581-602 (2008)
Looking into KPV? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA tripeptide antioxidant central to cellular redox, detoxification, and immune function.
Produced endogenously and supplemented via IV, injection, or oral routes; clinical evidence remains mixed.
A 28-residue peptide that modulates T-cell maturation and innate immune signaling.
Approved outside the U.S. for chronic hepatitis; domestic compounding remains ineligible after PCAC review.
A 37-residue antimicrobial peptide from the human cathelicidin family.
Broad roles in innate immunity and wound healing; named in the April 2026 HHS Category 2 withdrawal for PCAC re-evaluation.
“Advanced peptide therapies and personalized luxury care for optimal health, vitality, and longevity.”
Vetted providers offering KPV.